SCHEMBL29906159

SCHEMBL29906159

COc1c(C)c(O)c(Cc2c(O)c(C)c(O)c(C(=O)C(C)C)c2O)c(OC)c1C(=O)C(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FASN P49327 1/20 0.43
▸ PLA2G2A P14555 1/20 0.39
▸ ABCB1 P08183 1/20 0.36
▸ PTGES O14684 2/20 0.34
▸ ALOX5 P09917 2/20 0.34
▸ FFAR1 O14842 1/20 0.33
▸ PSMG3 Q9BT73 1/20 0.32
▸ IMPDH2 P12268 2/20 0.32
▸ LMNA P02545 2/20 0.31
▸ MEN1 O00255 2/20 0.31
▸ MAPT P10636 2/20 0.31
▸ KMT2A Q03164 2/20 0.31
▸ TP53 P04637 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ POLB P06746 1/20 0.30
▸ CYP3A4 P08684 1/20 0.30
▸ HPGD P15428 1/20 0.30
▸ GFER P55789 1/20 0.30
▸ NPSR1 Q6W5P4 1/20 0.30
▸ TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29929098 1.00 FASN (0.43) FASNPLA2G2AABCB1PTGESALOX5
SCHEMBL29929146 1.00 FASN (0.43) FASNPLA2G2AABCB1PTGESALOX5
SCHEMBL31578094 0.94 FASN (0.37) FASNPLA2G2AABCB1PTGESALOX5
SCHEMBL4742767 0.90 FASN (0.41) FASNPLA2G2AABCB1PTGESALOX5
SCHEMBL29658271 0.90 FASN (0.41) FASNPLA2G2AABCB1PTGESALOX5
SCHEMBL31289413 0.83 LMNA (0.43) FASNPLA2G2APTGESFFAR1LMNA
SCHEMBL27763321 0.80 FFAR1 (0.44) FASNABCB1PTGESALOX5FFAR1
SCHEMBL31232358 0.77 FASN (0.50) FASNPLA2G2AFFAR1LMNA
SCHEMBL30550440 0.77 FASN (0.50) FASNPLA2G2AFFAR1LMNA
SCHEMBL31623385 0.74 TP53 (0.32) PTGESALOX5IMPDH2MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250009655-A1 BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE Natural Extraction Systems, LLC 2025-01-09 — — US claimed
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 — — US claimed
WO-2023064318-A1 BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE Natural Extraction Systems, LLC (US) 2023-04-20 — — WO claimed
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 — — US claimed
WO-2022182523-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2022-09-01 — — WO claimed
WO-2022182527-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2022-09-01 — — WO claimed
US-20260048025-A1 COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES NATURAL EXTRACTION SYS LLC (US) 2026-02-19 — — US disclosed
US-12409152-B2 Compositions and methods related to dissolved oxides Natural Extraction Systems, LLC (US) 2025-09-09 — — US disclosed
US-12390418-B2 Biphasic compositions comprising one or both of carbonate and phosphate Natural Extraction Systems, LLC (US) 2025-08-19 — — US disclosed
US-20250161394-A1 Compositions Comprising Kavalactones NATURAL EXTRACTION SYS LLC (US) 2025-05-22 — — US disclosed
US-20250009655-A1 BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE Natural Extraction Systems, LLC 2025-01-09 — — US disclosed
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 — — US disclosed
WO-2023064318-A1 BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE Natural Extraction Systems, LLC (US) 2023-04-20 — — WO disclosed
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 — — US disclosed
US-20220362169-A1 COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES Natural Extraction Systems, LLC 2022-11-17 — — US disclosed
WO-2022182523-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2022-09-01 — — WO disclosed
WO-2022182527-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2022-09-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES FABP2, FABP4, GUSB FASN 1020/4885PLA2G2A 129/4885ABCB1 719/4885
US-12409152-B2 Compositions and methods related to dissolved oxides PRKG2, PRKG1, CIT FASN 1957/4885PLA2G2A 133/4885ABCB1 3834/4885
US-20260048025-A1 COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES SCO2, CNR2, CNR1 FASN 1507/4885PLA2G2A 119/4885ABCB1 4064/4885
US-20220362169-A1 COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES PRKG2, PRKG1, CIT FASN 1957/4885PLA2G2A 133/4885ABCB1 3834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback